The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume cakulated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple regresson analysis supported this notion. C-TK correlated with the proliferation-associated parameters, S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value. C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and tumour volume did provide additional information. It is conclue that the serum level of TK depends on both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that have died during the period immediately before sampling.
During cell proliferation, new DNA is synthesised. The synthesis of deoxythymidine triphosphate for DNA synthesis is either via the de novo pathway or via introduction of thymidine by means of thymidine kinase (TK). This enzyme, which is the only enzyme capable of introducing thymidine production, catalyses the phosphorylation of deoxythymidine to deoxythymidine monophosphate. Intracellular levels of TK increase when cells enter the late G, phase and decrease at mitosis (Sherley et al., 1988) .
Severeal studies have shown the prognostic value of the serum level of deoxythymidine kinase (S-TK) in nonHodgkdn lymphomas (NHL) (Ellims et al., 1981; Gronowitz et al., 1983; Hagberg et al., 1984a; Martinsson et al., 1988; Rehn et al., 1991) and in other tumour types such as Hodgkin's disease (Eriksson et al., 1985) , acute non-lymphoblastic leukaemia (Archimbaud et al., 1988) , small-cell lung cancer (Gronowitz et al., 1986; van der Gaast et al., 1991) , multiple myeloma (Simonsson et al., 1988; Luoni et al., 1991) , adenocarcinoma of the breast (Romain et al., 1990) and prostatic adenocarcinoma (Lewenhaupt et al., 1990) . In NHL, the S-TK level has in several studies been the strongest prognostic factor when compared with other serum markers, proliferation-associated parameters and clinical variables (Hagberg et al., 1984a; Martnsson et al., 1988; Rehn et al., 1991) . A study by Eng Gan et al. (1984) has indicated that the cellular levels of TK (C-TK) might also have prognostic value in NHL.
Apart from tumours, high S-TK values are also seen during the acute stage of certain viral infections (Gronowitz et al., 1984) and in megaloblastic anaemia caused by vitamin B12 deficiency (Hagberg et al., 1984b) .
Tbeoretically, elevated S-TK values could, in patients with a tumour, reflect the tumour burden, the tumour cell proliferation rate or the extent of tumour cell death. High-grade NHL is often an aggressive, fast-growing disease with a high rate of proliferation. In contrast, low-grade NHL often has a slower proliferation rate and a large tumour burden at diagnosis. The group as a whole thus comprises lymphomas with variable proliferation rates and variable tumour burdens.
Both the tumour cell proliferation rate and tumour burden carry prognostic information (Tubiana et al., 1986; Akerman et al., 1987; Donhuijsen et al., 1987; Young et al., 1987; Wooldrige et al., 1988; Rehn et al., 1990a) . Tumour cell death may also carry prognostic information in NHL (Rehn et al., 1990b) .
This study was performed in order to assess the contribution of the tumour burden and the tumour cell proliferation rate to S-TK levels and to explore whether C-TK levels reflect proliferation and carry prognostic information in NHL.
Maa and mthoPatients Eighty-nine patients with B-cell non-Hodgkin lymphomas (48 with low-grade NHL and 41 with high-grade NHL) were included in the study. The patient material was consecutive, provided that frozen tumour cells and serum, taken at diagnosis before treatment was initiated, were available. The patients were recruited between May 1980 and February 1992. The follow-up times range from 8 to 149 months (median 102 months). Estimations of S-phase and mitotic index were available in 67 and 65 patients respectively (Rehn et al., 1990a (Rehn et al., , 1991 . The lymphomas were classified according to the Kiel classification (Lennert, 1978) and clinical staging was performed according to the Ann Arbor system (Carbone et al., 1971) . This staging also takes B symptoms (fever, night sweats and weight loss) into consideration. The characteristics of the patients in terms of histological group, stage and age are shown in Table I .
Treatment
The treatment of stage I disease consisted in local extended radiotherapy in both low-and high-grade NHL. Patients with high-grade NHL stages II-IV received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) with or without methotrexate in a randomised trial S-phase fraction and mitotic index Estimations of the S-phase fraction and mitotic index were performed as previously described (Rehn et al., 1990a (Rehn et al., , 1991 .
Twnour volume calculation A more extended estimation of the tumour burden than that provided by the clinical stage was performed retrospectively by calculating the tumour volume (in cm3) from data in the patient files of findings from clinical examinations, radiological examinations (chest radiography, ultrasonography, computerised tomography or magnetic resonance imaging of the abdomen and, in some cases, of the thorax) and bone marrow examinations (aspirations from the sternum and core biopsies from the pelvic bones) which revealed the cellularity and the degree of lymphoma involvement. Clinical examination, chest radiography, at least one radiological abdominal examination and bone marrow examination were done in all patients. If the clinical records did not provide a distinct assessment of the size of any tumour manifestation, the X-rays or bone marrow aspirations were re-examined. The entire bone marrow volume was estimated to 2600 cm3, half of which was estimated to be red bone marrow (Block, 1976) . Only the proportion of marrow replaced with tumour cells was included in the tumour volume.
The estimated tumour volumes were grouped into three categories: small (< 50 cm3), medium (50 -500 cm3) and large (> 500 cm3).
Statistical methods
Differences in the distribution of values between two groups were tested with the Mann-Whitney U-test, and differences in the distribution of values for several subgroups were tested with the Kruskal-Wallis test. The correlation between different parameters was done with Spearman rank correlation test. These tests and the multiple regression calculations were performed with StatView 4.0 (Abacus Concepts, 1992).
LIFETEST was used to evaluate the prognostic capacity of the different variables (SAS Institute, 1985) . The log-rank test (Peto et al., 1976) was used. Patients dying of intercurrent diseases were not included in the population at risk after their death, provided they were in complete clinical remission. Best cut-off points were defined as the level yielding the highest 2-value, when equality over strata was tested with the log-rank test, provided that at least 15% of the cases had a value neither below nor above the cut-off level. The parameters were also tested as continuous variables. Multivariate analyses with the Cox's proportional hazards model were performed with Statistica 3.Ob software (Statsoft, 1993) . Chi-square and P-values in the multivariate analyses were obtained by Wald's test.
Results
C-TK in relation to S-phase fraction, mitotic index, histopathology and tunour volume A correlation was seen between C-TK and the two proliferation-associated parameters, S-phase fraction (r = 0.6, P = 0.0001) and mitotic index (r = 0.6, P= 0.0001). The correlatin between S-phase fraction and mitotic index was, however, somewhat higher (r = 0.8, P =0.0001).
High-grade NHL tumours had significantly higher C-TK values (Table I and II), S-phase fractions and mitotic indices than low-grade NHL (P = 0.0001 in all cases). Small and medium-sized tumours also had significantly higher values of C-TK (P= 0.002) (Table II) , S-phase fraction (P= 0.003) and mitotic index (P = 0.01) than large
tumours. An inverse correlation between C-TK and the numerical value of the tumour volume was seen in all patients and in high-grade NHL (r = -0.4, P = 0.0001, vs r = -0.3, P = 0.03). No correlation, however, was observed in the case of low-grade NHL (r =-0.1, P= 0.65).
When the C-TK levels of the four groups formed from low-or high-grade NHL together with 'small and mediumsized tumours' or 'large tumours' were compared, differences between the groups were seen (P =0.0003, Figure la) . In contrast, when the C-TK values were calculated per cell in 1101 A correlation between S-TK and the numerical value of tumour volume was seen in all patients (r = 0.4, P = 0.0001) and in both low-grade NHL (r = 0.6, P = 0.0001) and highgrade NHL (r= 0.8, P= 0.0001). The levels of S-TK differed significantly between the different Ann Arbor stages (P = 0.004; Figure 2a ) and the estimated tumour volume categories (P = 0.0001; Figure 2b ). S-TK in relation to tunour volume and C-TK Among all patients, there was no correlation between S-TK and C-TK (r = 0.2, P = 0.06) (Figure 3 In contrast to the lack of correlation between S-TK and C-TK in all patients, a correlation between S-TK and C-TK Th*mi. kim i Nl.
was seen within the three tumour volume categories (Table   II) . This correlation was not seen within the different stages according to Ann Arbor (data not illustrated). Within the different tumour volume categories, the levels of S-TK varied according to whether C-TK levels were above or below the median value (Table III) . Multiple regression analyses were performed to evaluate the relative importance of tumour volume and C-TK for the S-TK level. The values were then used in a logarithmic form in order to correct for different scaling. Both tumour volume and C-TK gave significant contribution to the variations in the S-TK level and the following relationship was found:
Log S-TK =-0.087 + 0.234 (log tumour volume) + 0.171 (log C-TK) The equation shows that tumour volume had the strongest relationship to the S-TK level (P = 0.0001). After the effect of the tumour volume was taken into account, C-TK also contributed to the S-TK level (P = 0.009).
B symptoms in relation to histopathology, tumour volwne and TK levels Sixty-three per cent (20/32) of the patients with B symptoms had high-grade NHL. More high-grade NHL patients than low-grade NHL patients (P = 0.02) ( No patient within the small tumour volume category had B symptoms, whereas almost half of the patients with medium and large tumour volumes had B symptoms (data not illustrated).
Patients with B symptoms had significntly higher S-TK levels (P= 0.002) and slightly higher C-TK values (P = 0.03) than patients without B symptoms. Of the patients with medium and large tumour volumes, the patients with B symptoms had much higher C-TK values (mean 6982 units 10' cells) than patients without B symptoms (mean 3332 units 10-6 cells, P = 0.007).
Relations to prognosis S-TK, C-TK and tumour volume all carried prognostic information for the patient sample as a whole (Figure 4 ), in patients with low-grade NHL and, with the exception of C-TK, in patients with high-grade NHL (data not illustrated). The separation of the variables into two prognostic groups is in the case of C-TK, most useful after a short-term follow-up, and in the case of tumour volume after a long- term follow-up, whereas S-TK separates the prognostic groups after both a short-and long-term follow-up ( Figure  4) . Stage also had prognostic value (log-rank P = 0.03), whereas histological grade provided no prognostic information (log-rank P = 0.20). In multivariate analyses involving S-TK, C-TK and tumour volume (or stage) and the histological grade, S-TK showed superior prognostic strength and no additional information was provided by any of the other parameters (data not illustrated). In order to explore further the relations between S-TK, C-TK and tumour volume, their association to prognosis was tested in separate multivariate analyses including all three variables or only two of them. It was found that neither tumour volume nor C-TK gave any prognostic information additional to S-TK (Table MV ). In the absence of S-TK, C-TK and tumour volume each provided additional prognostic information (Table IV) . Using log-transformed data or using the vairables in dichotomised form did not change the results (data not illustrated).
The prognostic value of S-TK in patients with NHL is well established (Ellims et al., 1981; Gronowitz et al., 1983; Hagberg et al., 1984a; Mariinsson et al., 1988; Rehn et al., 1991) . It has been suggested that S-TK reflects both tumour cell proliferation rate and tumour volume (Rehn et al., 1991; van der Gaast et al., 1991; Luoni et al., 1991) , both of which are of prognostic importance. The results of this study strongly suggest that S-TK reflects the tumour volume in partcular, but also the proliferation rate. In certain other tumour types, S-TK has also been found to be correlated to tumour burden and is elevated in higher stages [Simonsson et al., 1988; Luoni et al., 1991 (multiple stage, which was orginally developed for HD, is not particularly strong in NHL (Leonard et al., 1983 ). Yet, staging according to Ann Arbor is in routine use as regards therapy decisions and is used for comparing results from different trials. This is probably because of its simplicity. Attempts to replace this staging system by other tumour burden assessments have failed to come in routine clnical use. Since the tumour burden assessment in this study was performed retrospectively, uncertainties may exist, and it is not our intention to advocate its routine use. However, we beLieve that it carries some validity, particularly after categorisation into small, medium and large volumes, in the exploration of the importance of tumour burden as regards S-TK levels.
C-TK correlated well with other proliferation-associated factors, supporting the idea based upon theoretical considerations that the level of C-TK reflects proliferation. S-phase fraction and mitotic index are also, like C-TK, significantly higher in high-grade NHL than in low-grade NHL. Interestingly, although patient numbers were small within the lowgrade NHL group, the highest C-TK levels were found in the two groups with an intermediate prognosis, namely centrocytic lymphomas and follicular and diffuse centroblastic-centrocytic lymphomas (Martinsson et al., 1988 ). The C-TK level per cell in mitosis (or per cell in S-phase) in patients with high-and low-grade NHL with 'small and medium sized' or 'large' tumour volumes, respectively, did not differ significantly between the groups, indicating that the content of C-TK in cells in which C-TK is expressed (Sphase, G2 or mitosis) is very much the same despite the large variability in proliferation rates.
Even if there was no correlation between S-TK and C-TK in the patient sample as a whole, the correlations between these parameters seen within each tumour volumes group suggest that the S-TK level depends not only upon the tumour volume, but also upon the cell content of TK, and thus also reflects cell proliferation. Also, despite significntly larger tumour volumes in the low-grade NHL group visi--vis the high-grade NHL, S-TK was significantly higher in patients with high-grade NHL than low-grade NHL. Multiple regression analyses showed that tumour volume had the strongest relationship to the S-TK level but that C-TK provided additional information after the tumour volume was taken into account. Further support for the importance of both C-TK and tumour volume as regards the levels of S-TK comes from multivariate analyses, in which C-TK and tumour volume showed additional prognostic importance but neither C-TK, nor tumour volume added any significnt information to that provided by S-TK.
The finding that the C-TK values were higher in patients with small or medium-sized tumours (<500 cm3) than in patients with large tumours probably rlects the fact that rapidly proliferating tumours become symptomatic much earlier than slowly proliferating ones. In fact, not a single patient with NHL had both high C-TK and high S-TK levels at diagnosis. In patients with acute lymphatic leukaemia, which is usually a highly proliferative disease, very high S-TK level may be seen (Hagberg et al., 1984c) . The C-TK levels in the tumour cells of patients with ALL collected in vivo showed levels of the enzyme as high as in high-gade NHL (Vertongen et al., 1984) . It is known that the tumour volumes in patients with acute leukaemia are generaly higher than in patients with the closely related lymphoblastic lymphoma. Untreated patients suffering from acute leukaemias have a very short survival, indicating that both high cell proliferation rate (high C-TK) and a large tumour burden are incompatible with prolonged life.
This study does not explore how cellular TK reaches the blood, although one possible explanation may be through cell death. We have, in a number of patients with NHL, seen a signifiant increase in S-TK during the days immediately after chemotherapy administration, with peak levels after 24-48 h (own unpublished observations). The half-life of S-TK has been estimated to be less than 2 days (Gronowitz and Killander, 1984) . Catalano et al. (1990) have also shown an increase in S-TK 12-48 h after intensive chemotherapy in patients with acute myelogenous leukaemia with a reduction or normalisation, parallel with the blast cell disappearance in blood, during the following days. Elevated S-TK values are seen in patients with megaloblastic anaemia as a result of vitamin Bt2 deficiency (Hagberg et al., 1984c) . In that condition, enhanced TK values are also found in the bone marrow (Nakao et al., 1968) , and it is proposed that the haemolysis of proliferating immature cells gives rise to the S-TK elevation (Hagberg et al., 1984c) . We therefore suggest that the level of TK in serum reflects to a great extent the number of proliferating cells that have died within a few days of the sampling, even if a release of TK from 'healthy' proliferating cells cannot be excluded. Bristow et al. (1988) in fact showed that proliferating cells in culture release TK into the surrounding medium. In studies of liver regeneration in rats, S-TK and C-TK rise simultaneously (Polimeno et al., 1991 ). An elevation of S-TK after liver resections is also seen in humans (Francavilla et al., 1990) .
In tumour sections, areas of tumour cell necrosis are seen in high-grade NHL but rarely in low-grade NHL (own unpublished observations). A heterogeneous appearance, when investigated with magnetic resonance imaging (MRI), of high-grade NHL, as opposed to low-grade NHL, is most likely a reflection of tumour cell necrosis (Rehn et al., 1991) , observations indicating cell death in rapidly proliferating tumours. Preliminary analyses have shown that patients with stage I disease (often low tumour volume) have a good prognosis despite the MRI appearance (homogeneous or heterogeneous), whereas, in stages II-IV, the prognosis is poorer for heterogeneous tumours (Rehn et al., 1991) . These results thus also fit in with our suggestion.
In conclusion, this study provides evidence that the levels of TK in serum depend both on the tumour burden and upon the cellular content of TK, i.e. cell proliferation. This fact may explain TK's strong prognostic importance in patients with malignant lymphomas and why it is superior to most other strong predictors in a number of studies (Hagberg et al., 1984a , Martinsson et al., 1988 Rehn et al., 1991) .
